NEW DELHI, March 24, 2026 /PRNewswire/ — According to the latest research report published by MarkNtel Advisors, the Global Plasma Fractionation Market is projected to grow at a CAGR of around 6.15% during 2026–2032. The market growth is primarily driven by the increasing prevalence of immunological and hematological disorders, rising demand for plasma-derived therapies, expanding applications of immunoglobulins, and advancements in plasma processing technologies.
Regionally, North America leads the Global Plasma Fractionation Market, accounting for approximately 54% of the total market share in 2026. The region’s dominance is supported by well-established plasma collection infrastructure, strong presence of leading biopharmaceutical companies, high healthcare expenditure, and increasing awareness regarding plasma-derived therapeutics.
Global Plasma Fractionation Market Key Takeaways
- The Global Plasma Fractionation Market was valued at USD 32.1 billion in 2025 and is projected to grow from USD 35.7 billion in 2026 to USD 51.06 billion by 2032, reflecting steady market expansion driven by rising demand for plasma-derived therapies and growing clinical applications.
- By product type, Immunoglobulins accounted for nearly 60% of the market share in 2026, driven by their extensive use in treating primary and secondary immunodeficiency disorders, autoimmune diseases, and neurological conditions.
- By application, the Immunology segment captured approximately 36% of the Global Plasma Fractionation Market in 2026, supported by increasing diagnosis rates of immune-related disorders and expanding therapeutic indications.
- The presence of leading global and regional biopharmaceutical companies continues to strengthen the competitive landscape through investments in plasma collection networks, product innovation, and advanced fractionation technologies.
Download a FREE PDF Sample of the Report https://www.marknteladvisors.com/query/request-sample/plasma-fractionation-market.html (Discover the market potential, emerging technologies, and key industry insights.)
Core Drivers Supporting the Global Expansion of Plasma Fractionation
- Rising Prevalence of Immunological and Rare Disorders
The increasing global burden of immunological and rare disorders is a primary factor driving the demand for plasma-derived therapies. Conditions such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenic purpura (ITP), and hereditary angioedema are witnessing a steady rise in diagnosis rates worldwide.
As a result, plasma-derived products, particularly immunoglobulins, have become essential in managing these conditions by enhancing immune response and improving patient outcomes. Furthermore, growing awareness, improved screening programs, and advancements in diagnostic capabilities are contributing to earlier detection and treatment, thereby significantly boosting the demand for these life-saving therapies.
- Growing Demand for Immunoglobulins Across Therapeutic Areas
Building on the rising disease burden, immunoglobulins continue to serve as the cornerstone of plasma fractionation, owing to their extensive application across immunology, neurology, hematology, and infectious disease treatments. The increasing clinical adoption of intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) therapies is further accelerating market growth.
In addition, the growing preference for home-based care and long-term disease management solutions is supporting the rapid uptake of SCIG therapies. This shift not only enhances patient convenience and treatment adherence but also reduces the burden on healthcare facilities, thereby reinforcing the overall demand for immunoglobulin products.
- Advancements in Plasma Processing and Fractionation Technologies
Alongside rising therapeutic demand, continuous advancements in plasma processing and fractionation technologies are playing a crucial role in shaping market growth. Modern techniques such as chromatography, nanofiltration, and advanced viral inactivation methods are significantly improving the purity, safety, and efficiency of plasma-derived products.
Moreover, the integration of innovative filtration systems and hybrid processing technologies is enabling manufacturers to optimize plasma utilization and scale production effectively. These technological improvements are essential in meeting the growing global demand while maintaining stringent safety and quality standards.
Key Obstacles Affecting the Global Plasma Fractionation Market Growth
- Limited Plasma Supply and High Production Complexity
Despite the strong growth outlook, the plasma fractionation market faces notable challenges related to limited plasma supply and the complexity of production processes. Plasma collection remains highly regulated and heavily dependent on donor availability, which can lead to supply constraints and impact product availability.
Furthermore, the fractionation process involves sophisticated infrastructure, rigorous quality control measures, and strict regulatory compliance, all of which contribute to high operational costs. However, increasing investments in plasma collection networks, along with ongoing technological advancements, are expected to gradually alleviate these challenges and support sustainable market expansion in the coming years.
Market Analysis by Product Type, Application & Region
By product type, immunoglobulins dominated the Global Plasma Fractionation Market, accounting for nearly 60% share in 2026, primarily due to their extensive therapeutic applications in treating immune deficiencies, autoimmune disorders, and neurological conditions. Their widespread clinical adoption, coupled with increasing demand for intravenous and subcutaneous formulations, continues to reinforce segment growth. In addition to immunoglobulins, other product categories such as coagulation factor concentrates and albumin are contributing significantly to overall market expansion. These products play a critical role in hemophilia treatment, surgical care, and critical care management, thereby supporting consistent demand across diverse medical settings globally.
By application, the immunology segment held a leading share of approximately 36% in 2026, driven by the rising prevalence of immune deficiencies and autoimmune disorders worldwide. The growing need for effective long-term treatment solutions has significantly increased the adoption of plasma-derived therapies within this segment. Furthermore, advancements in diagnostic capabilities and improved disease awareness are contributing to early intervention and higher treatment rates. Alongside immunology, other application areas such as neurology and hematology are gaining considerable traction, supported by the expanding clinical use of plasma-derived products in managing neurological disorders, bleeding conditions, and other chronic diseases.
Regionally, North America dominated the Global Plasma Fractionation Market, capturing approximately 54% of the total market share in 2026. This leadership is attributed to the region’s advanced healthcare infrastructure, well-established plasma collection networks, and the strong presence of leading biopharmaceutical companies. Additionally, high healthcare expenditure and favorable regulatory frameworks further support market growth in the region.
View Full Report (All Data, In One Place) https://www.marknteladvisors.com/research-library/plasma-fractionation-market.html (Explore in-depth analyses, technology trends, and investment opportunities.)
Innovation Momentum Driving Advancements in Plasma Therapies and Patient-Centric Care
The Global Plasma Fractionation Market is witnessing steady progress driven by continuous innovation, regulatory approvals, and a growing focus on enhancing patient convenience. In June 2025, CSL achieved a significant milestone with the U.S. Food and Drug Administration approval of ANDEMBRY® (garadacimab-gxii) for the prophylactic treatment of hereditary angioedema (HAE) in patients aged 12 years and older. Notably, this therapy represents the first treatment targeting factor XIIa at the initiation of the HAE cascade. Its once-monthly, subcutaneous autoinjector format not only reduces the frequency of HAE attacks but also expands preventative treatment options for patients suffering from this rare and potentially life-threatening condition.
Building on this momentum, in July 2025, Takeda announced that the U.S. FDA granted 510(k) clearance for its HyHub™ and HyHub™ Duo vial access devices, designed to simplify the administration of HYQVIA®, a plasma-derived immunoglobulin therapy. These single-use devices are aimed at reducing preparation steps for subcutaneous infusion, thereby improving ease of use in both home and clinical settings. Developed with direct input from patients and caregivers, the devices are expected to be available in the U.S. in the second half of 2025. This advancement underscores the industry’s growing emphasis on patient-centric innovations and improved treatment accessibility.
Major Plasma Fractionation Companies Operating Worldwide
Key companies shaping innovation and competition include:
- CSL Behring
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Kedrion Biopharma
- ADMA Biologics, Inc.
- Bharat Serums and Vaccines Limited
- Intas Pharmaceuticals Ltd.
- Shanghai RAAS Blood Products Co., Ltd.
- Merck KGaA
- Biotest AG
- Emergent BioSolutions Inc.
- Kamada Ltd.
- GC Biopharma Corp.
- PlasmaGen BioSciences Pvt. Ltd.
- LFB
- Syntegon
- Others
Global Plasma Fractionation Market Scope
By Product Type: Immunoglobulins (IVIG, SCIG, Hyperimmune Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrates (PCC), Fibrinogen Concentrates, Others), Albumin, Protease Inhibitors (Alpha-1 Antitrypsin, C1 Esterase Inhibitors, Others)
By Application: Hematology, Immunology, Neurology, Oncology, Critical Care & Trauma, Pulmonology, Rheumatology, Dermatology, Infectious Diseases, Others
By Processing Technology: Chromatography, Ultrafiltration & Microfiltration, Nanofiltration & Viral Inactivation, Recombinant/Hybrid Processing
By Disease Indication: Primary & Secondary Immunodeficiency, Hemophilia A & B, CIDP, ITP, Kawasaki Disease, Hereditary Angioedema, Others
By End User: Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes
By Region: North America, South America, Europe, Middle East & Africa, Asia-Pacific
Browse More Reports
Global Cold Plasma Market: The Global Cold Plasma Market size was valued at around USD 2.2 billion in 2024 and is projected to reach USD 4.2 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 11% during the forecast period (2025-30).
GCC Geographical Atrophy market: The GCC Geographical Atrophy Market size was valued at around USD 1.05 billion in 2025 and is projected to grow from USD 1.41 billion in 2026 to USD 5.01 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 23.63% during the forecast period, i.e., 2026-32.
Saudi Arabia Digital Therapeutics Market: The Saudi Arabia Digital Therapeutics Market size is valued at around USD 34 million in 2025 and is projected to reach USD 62 million by 2032. Along with this, the market is estimated to grow at a CAGR of around 8.96% during the forecast period, i.e., 2026-32.
Global Digital Therapeutics Market: The Global Digital Therapeutics Market is estimated to grow at a CAGR of around 20% during the forecast period, i.e., 2024-30.
Global Brachytherapy Devices Market: The Global Brachytherapy Devices Market is projected to grow at a CAGR of around 7.0% during the forecast period, i.e., 2024-2029.
Global Negative Pressure Wound Therapy Market: The Global Negative Pressure Wound Therapy Market is projected to grow at a CAGR of around 6.1% during the forecast period, i.e., 2023-28.
Global mRNA Vaccines and Therapeutics Market: The Global mRNA Vaccines and Therapeutics Market is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26.
About MarkNtel Advisors
MarkNtel Advisors is a leading market research and consulting firm committed to delivering reliable, data-driven insights across diverse global industries. Our research combines extensive primary interviews with industry experts and carefully validated secondary data to ensure accurate and credible market intelligence. With deep sector expertise and a team of experienced analysts, we empower businesses and investors with strategic insights that support informed decision-making in rapidly evolving market environments.
Contact Us:
MarkNtel Advisors
Office No.109, H-159, Sector 63, Noida, Uttar Pradesh – 201301, India
Contact No: +91 87199 99009
Email: [email protected]
Website: marknteladvisors.com
Logo: https://mma.prnewswire.com/media/2687299/5876657/MarkNtel_Advisors_Logo.jpg
View original content:SOURCE MarkNtel Advisors
